Protagonist Therapeutics, Inc 4

President and CEO Dinesh V. Patel, Ph.D. exercised 100,000 stock options at $21.58 and sold the resulting 100,000 Protagonist Therapeutics (PTGX) shares around $149 per share under a Rule 10b5‑1 plan, leaving him with 523,478 shares owned directly.

On August 10 and 11, 2026, Protagonist Therapeutics President and CEO Dinesh V. Patel, Ph.D. exercised expiring stock options for a total of 100,000 shares of common stock at an exercise price of $21.58 per share and immediately sold the same 100,000 shares pursuant to a pre‑arranged Rule 10b5‑1 trading plan adopted on January 30, 2026. On August 10, he exercised 65,761 options and acquired 65,761 shares at $21.58, then sold 65,761 shares at a weighted average price of $149.11, and on August 11 he exercised a further 34,239 options and acquired 34,239 shares at $21.58, then sold 34,239 shares at a weighted average price of $148.52, with sale prices in each case executed over multiple trades in the high‑$140s to low‑$150s. Following these planned option exercise-and-sell transactions, which monetized roughly $12–13 million of value while clearing near‑term expiring options, Patel reported direct ownership of 523,478 shares of Protagonist Therapeutics common stock, representing a substantial continuing equity stake.

Filing Facts

CIK

1377121

Ticker

PTGX

Form

4

Source Type

fda

Accession

0001104659-26-095111

Alert Tier

7